EGFR and non-small cell lung carcinoma: Moreover, a phase II trial has shown that EGFR wild-type patients with advanced NSCLC treated with cabozantinib alone or in combination with erlotinib had improved PFS (cabozantinib alone 4.3 months, HR 0.39, 80% CI 0.27–0.55; cabozantinib and erlotinib 4.7 months, HR 0.37, 80% CI 0.25–0.53) compared to erlotinib alone (1.8 months, 95% CI 1.7–2.2) [72].